舒肝解郁胶囊治疗轻中度精神分裂症后抑郁的疗效观察

Observation on Efficacy of Shuganjieyu Capsule in Treatment of Mild to Moderate Post-Schizophrenic Depression

目的:观察中药舒肝解郁胶囊治疗精神分裂症后抑郁的临床疗效、不良反应及安全性。方法:将60例诊断为精神分裂症后抑郁的轻中度患者随机分为两组,分别为治疗组(舒肝解郁胶囊组)和对照组(西酞普兰组),共治疗6周,采用汉密尔顿抑郁量表(HAMD)、简明精神病评定量表(BPRS)及不良反应量表(TESS),分别与治疗前和治疗2、4、6周末分别评定疗效和不良反应症状。结果:舒肝解郁胶囊与西酞普兰治疗后HAMD、BPRS评分均较治疗前降低(P<0.01),两组间统计无显著差异(P>0.05);舒肝解郁胶囊显效率为86.6%,西酞普兰为90%,两组疗效差异无统计学意义(P>0.05)。舒肝解郁胶囊不良反应症状较西酞普兰少,差异有统计学意义(P<0.05)。结论:舒肝解郁胶囊治疗精神分裂症后抑郁的临床疗效好,安全性高,不良反应较轻。

Objective To observe the clinical efficacy,adverse reactions and safety of Shuganjieyu capsule in treating Post - Schizophrenic Depression. Methods 60 patients diagnosed as schizophrenic with mild to moderate depression were randomly divided into the treatment（Shuganjieyu Capsule） group and the control（citalopram） group,treated for 6 weeks.The therapeutic efficacy and adverse reactions were evaluated before treatment and 2,4,6 weeks after treatment with Hamilton Depression Rating Scale（HAMD）,Brief Psychiatric Rating Scale（BPRS） and the adverse effects scale（TESS）.Results After the treatment,the scores of HAMD and BPRS were significandy lower than those before treatment（P 0.01）,and no statistically significant difference was found between the two groups（P 0.05）.There were no statistically significant difference of the efficacy between Shuganjieyu Capsules and citalopram,with the effective rates of 86.7%and.90%.The adverse reaction of Shuganjieyu capsule was significantly less than that of citalopram（P 0.05）.Conclusion Shuganjieyu capsule in treatment of Post - Schizophrenic Depression is effective,safe,with less adverse reactions.